key: cord-0686750-74qxuhpz
authors: Karagiannidis, Christian; Windisch, Wolfram; McAuley, Daniel F; Welte, Tobias; Busse, Reinhard
title: Major differences in ICU admissions during the first and second COVID-19 wave in Germany
date: 2021-03-05
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(21)00101-6
sha: 64013c186bfe9a0ac18efade9c9f745b1922a130
doc_id: 686750
cord_uid: 74qxuhpz

nan

The mortality of mechanically ventilated patients with COVID-19 in German intensive care units (ICUs) during the first wave of the pandemic was reported to be 53%. 1 Several treatment options for patients with COVID-19 have been established since then. Corticosteroid treatment has been established for severely ill patients [2] [3] [4] and in light of the ongoing RECOVERY trial (NCT04381936), IL-6 blockade might have an advantage in patients with organ failure, including the prevention of progression to mechanical ventilation in those receiving noninvasive respiratory support. It is, thus, suggested that this, as part of a bundle of different measures, may have impacted on the ICU admission rate and outcome. We, therefore, have analysed the data from the federal German hospital payment institute (Institut für das Entgeltsystem im Krankenhaus [InEK]) at the time of discharge of patients with COVID-19 from all hospitals in Germany in 2020, including data from both the first and second waves of the pandemic.

During 2020, the proportion of hospitalised patients requiring ICU treatment steadily dropped from 30% during the period of our previous analysis 1 (ie, discharge up to week 23) to 14% in December (weeks 49-52), corresponding to a relative drop in ICU admissions of more than 50%. Additionally, the percentage of those being mechanically ventilated while in the ICU also dropped, from 64% up to week 23, to 54% in weeks 49-52 (ie, from 19% of all hospitalised patients with COVID-19 to less than 8%). However, the absolute number of patients requiring mechanical ventilation in the ICU steadily increased during the second wave (figure 1) and almost doubled compared with that of the first wave.

Mortality in patients being mechanically ventilated in the ICU remained unchanged at above 50% for the entire observational period (figure 1). We also found only minor changes in the mean age of survivors and non-survivors (figure 1). Although we cannot exclude that restrictions in ICU admission criteria might have occurred, resulting in these reduced ICU admission rates, the stable age distribution of ICU patients suggests that Germany did not experience a shortage of ICU capacity. This interpretation is supported by daily reports on nationwide ICU capacities, which allowed for optimal distribution of critically ill patients with COVID-19.

Finally, patients without mechanical ventilation requiring ICU treatment had a good prognosis, with a mortality rate of 10-38%, depending on the week of the second wave, almost similar to that of the first wave ( figure 2) .

Overall, our analysis clearly suggests a dramatic improvement in the management of patients with COVID-19. Compared with in the first wave, 50% less of all hospitalised patients were admitted to the ICU during the second wave of the pandemic. By contrast, the analysis also clearly shows that the prognosis of ICU patients, those requiring mechanical ventilation and those not, 17  15  18  13  16  14  20  28  30  26  24  27  22  25  23  29  37  39  35  33  36  31  34  32  38  46  48  44  42  45  40  43  41  47  50  52  49  51 Week First, changes in the use of highflow oxygen treatment and noninvasive ventilation with more clearly defined algorithms being available when these treatment strategies need to be escalated to invasive mechanical ventilation. 5 Second, the establishment of pharmacological treatments, with the greatest treatment success most likely to be achieved by the early administration of dexamethasone in patients with severe COVID-19. 2 One limitation of these data is that there was no information on comorbidities. In conclusion, given that approximately 5700 patients with COVID-19 were in German ICUs at the end of December 2020, the profound decrease in ICU admissions was a key factor in avoiding unmanageable ICU shortages.

CK reports personal fees from Maquet, Xenios, and Bayer; non-financial support from Speaker of the 17  15  18  13  16  14  20  28  30  26  24  27  22  25  23  29  37  39  35  33  36  31  34  32  38  46  48  44  42  45  40  43  41  47  50  52  49  51 Week Discharged Died

Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study

Dexamethasone in hospitalized patients with COVID-19-preliminary report

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Recommendations on inpatient treatment of patients with COVID-19